



**Resonance Health Ltd**  
**ASX / Media Release**

**15 September 2014**

---

## **Resonance Raises a Further \$650,000**

Resonance Health Limited (**ASX: RHT**) (**Resonance** or **the Company**) is pleased to confirm that it has raised a further \$650,000 through the placement of 13million shares at an issue price of \$0.05 per share as part of the shortfall from the recent Entitlement Offer. When combining the proceeds raised pursuant to the Placement and Entitlement Offer, a total of \$1.9million has now been raised. Following completion of the shortfall placement, the Company has a net cash balance of approximately \$2.7million.

Resonance Health has placed the majority of the funds with a significant institutional investor and we welcome them to our register.

The completed funding provides the capital resources to pilot HepaFat Scan into the US, Europe and Asia market, to participate in pivotal validation studies and fund ongoing Fibrosis work.

The ability to undertake validation studies will further build and enhance on the credentials of our MRI based technologies around the globe.

In accordance with the ASX Listing Rules the Company had 3 months from the date the Entitlement Offer closed (13 June 2014) to place any shortfall which expires today.

For further information please contact:

**Resonance Health**

Adrian Bowers

Company Secretary

T: +61 8 9286 5300

E: [adrianb@resonancehealth.com](mailto:adrianb@resonancehealth.com)

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing imaging core laboratory services for the quantitative analysis of MR medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.